(Q33910315)

30 July 2017

1 reference

title

Hit HIV-1 hard, but only when necessary (English)

1 reference

30 July 2017

M Harrington

1

1 reference

30 July 2017

C C Carpenter

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

355

1 reference

30 July 2017

issue

9221

1 reference

30 July 2017

page(s)

2147-2152

1 reference

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Benchmarks for antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Strategies for long-term success in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Fat distribution and metabolic changes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Linkage disequilibrium test implies a large effective population number for HIV in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Therapeutic Strategies for HIV Infection — Time to Think Hard

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Changes in thymic function with age and during the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902388-6

7 January 2021

10.1016/S0140-6736(00)02388-6

Identifiers

DOI

1 reference

30 July 2017

1 reference